Callgrinitide 5mg

Cagrilintide is an investigational, long-acting amylin analogue being developed by Novo Nordisk for weight management and type 2 diabetes. When used as a standalone or combined with semaglutide (a combination known as "CagriSema"), clinical trials have shown it induces substantial weight loss.How It WorksMechanism: Cagrilintide mimics amylin, a hormone co-secreted with insulin by the pancreas. It targets receptors in the brain to reduce appetite, increase feelings of fullness (satiety), and slow down stomach emptying.The "CagriSema" Effect: While cagrilintide alone results in about 12% weight loss, combining it with semaglutide targets multiple pathophysiological pathways. This combination has resulted in clinical weight reductions exceeding 20% in trial settings, significantly outperforming semaglutide alone.